Q1 2022 ANALYST CALL & WEBCAST

May 4, 2022

DISCLAIMER

This presentation has been prepared by the Company. “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the meeting. This presentation does not constitute or form part of any offer to sell or issue, or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company or any of its subsidiaries (together the “Group”) or in any other entity, nor shall this presentation or any part of it, or the fact of its presentation, form the basis of, or be relied on in connection with, any contract or investment activity nor does it constitute a recommendation regarding the securities of the Group. Past performance, including the price at which the Company’s securities have been bought or sold in the past and the past yield on the Company’s securities, cannot be relied on as a guide to future performance. Nothing herein should be construed as financial, legal, tax, accounting, actuarial or other specialist advice and persons needing advice should consult an independent financial adviser or independent legal counsel. Neither this presentation nor any information contained in this presentation should be transmitted into, distributed in or otherwise made available in whole or in part by the recipients of the presentation to any other person in any jurisdiction which prohibits or restricts the same except in compliance with or as permitted by law or regulation. Recipients of this presentation are required to inform themselves of and comply with all restrictions or prohibitions in such jurisdictions.

Accordingly, by requesting to receive and reviewing this document you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you. No responsibility is accepted by and, to the fullest extent permitted by law, the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents expressly disclaim any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, as to the accuracy, fairness, reliability or completeness of the information contained herein or discussed verbally or as to the reasonableness of any assumptions on which any of the same is based or the use of any of the same or for any errors, omissions or misstatements in or from this presentation. No representations or warranties, express or implied, are given by the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents as to the accuracy, reliability or completeness of this presentation or any other written or oral information which has been or may be made available. Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the information contained herein, or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them. No duty of care is owed or will be deemed to be owed to any person in relation to the presentation. No reliance whatsoever may be placed on the presentation for any purpose. By accepting this presentation, you agree to use and maintain any such information in accordance with your contractual obligations and applicable laws, including all applicable securities laws. The information contained in this presentation has not been independently verified.

The Amryt logo, Myalept®, Myalepta®, Juxtapid®, Lojuxta®, Filsuvez® and Mycapssa® and other trademarks or service marks of Amryt appearing in this presentation are the property of Amryt. This presentation includes trademarks, tradenames and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this presentation appear without the ®, TM and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Filsuvez® (Oleogel-S10/birch triterpenes/formerly known as AP101) is currently an investigational product and has not received regulatory approval by the FDA or EMA. Elements of this presentation only apply in the event that Filsuvez® is approved by the appropriate regulatory authorities. Mycapssa® has been approved by the FDA for the long-term maintenance treatment in patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide but remains an investigational drug outside the US and for other indications. This presentation is intended only for communications with investors.

FORWARD-LOOKING STATEMENTS

This presentation may contain forward-looking statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this communication are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, and actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond each of Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions.

The delivery of this presentation shall not give rise to any implication that there have been no changes to the information and opinions contained in this presentation since the time specified. Subject to obligations under the Securities and Exchange Commission (“SEC”) (as amended from time to time), none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes to publicly update or revise any such information or opinions, including without limitation, any forward-looking statement or any other statements contained in this presentation, whether as a result of new information, future events or otherwise. In giving this presentation none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes any obligation to provide the recipient with access to any additional information or to update any additional information or to correct any inaccuracies in any such information which may become apparent. Certain industry and market data contained in this presentation has been obtained from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies or surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, scientific and market data contained in this presentation comes from the Company’s own internal case studies, research and estimates based on the knowledge and experience of the Company’s management in the market in which it operates. While the Company believes that such research, estimates and results from its case studies are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness unless otherwise stated and are subject to change without notice. Risks and uncertainties affecting the Company are outlined further in the Company SEC filings.

CONSISTENT PERFORMANCE AND GROWTH

Q1 2022 AND RECENT HIGHLIGHTS

- 22.1% YoY revenue growth in Q1 2022 to $59.1M (Q1 2021 $48.4M)
- 25.7% revenue growth in metreleptin Q1 2022 to $37.6M (Q1 2021 $30.0M)
- Generated EBITDA** (excluding restructuring & acquisition costs) of $7.2M in Q1 2022. 9th consecutive quarter of positive EBITDA generation.
- Cash of $102.2M at March 31, 2022
- Board approved stock repurchase program of up to $30M through March 2023
- Relaunch of Mycapssa® ongoing and progressing well
- **CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB**
- **FY 2022 revenue guidance reaffirmed of $260M - $270M, representing 17-21% YoY growth**



2022 Revenue guidance does not include any contribution for Filsuvez®

* Unaudited combined revenues for 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Amryt of Aegerion happened on 1 January 2019. These amounts (i) exclude revenues from sales to end-users in Japan, due to the out-licencing of lomitapide (Juxtapid®) to Recordati, which occurred in February 2019, (ii) exclude up-front payments from Recordati in 2019, and (iii) include a 22.5% royalty on Japanese sales of lomitapide (Juxtapid®) from 1 January 2019, as if the Recordati agreement were in place from that date. ** See non-GAAP/IFRS reconciliation ***Management estimates

METRELEPTIN - STRONG GROWTH GLOBALLY

GLOBAL METRELEPTIN REVENUE GROWTH OF **25.7%** YOY IN 2022





- 25.7% increase in metreleptin revenues YoY to $37.6M in 2022 (Q1 2021: $30.0M)
- US accounted for 53.8% of global metreleptin revenues in Q1 2022, 24.7% growth YoY
- EMEA accounted for 42.3% in Q1 2022, 22.8% growth YoY

AMRYT PHARMA

LOMITAPIDE

GLOBAL LOMITAPIDE REVENUE DOWN **2.0%** VERSUS Q1 2021





- Lomitapide revenues $17.8M in Q1 2022 (Q1 2021: $18.2M); increased by 0.7% QoQ
- US accounted for 45.2% of global lomitapide revenues in Q1 2022; EMEA accounted for 40.4%
- ROW accounted for 14.4% of global lomitapide, 6.3% YoY growth

AMRYT PHARMA

MYCAPSSA® - RELAUNCH INITIATED

Q1 Highlights – Underlying 11% revenue growth

Relaunch initiated in Q4 2021 – on track

Mycapssa® delivered $3.4M revenue in Q1. Allowing for the forward ordering in December 2021, used in Q1 2022 this would have been $4.4M

Sequential growth of 11% in Q1, adjusted for this inventory build



Market Positioning

New messaging to support transition to oral Mycapssa®

Enhanced HCP Focus

Cross-functional integration at the community level

Sales expanded focus beyond PTCs into community endocrinologists

Medical continued focus on PTCs

March approaching ~4.5 calls/day with the majority now in person

Improved Patient Support

The time between enrollment to patients receiving Mycapssa® continues to improve

ACE team focused on new patient starts, at risk patients and inactive patients

AMRYT PHARMA

MYCAPSSA® - DEVELOPMENT AND REGULATORY TIMELINE FOR NET PROGRAM

Q3 2021 - FDA agreed that a single positive Phase 3 study would be sufficient for approval in neuroendrocrine tumors (NET) patients with carcinoid symptoms, consistent with the 505(b)(2) regulatory pathway

The Agency recommended that the primary endpoint in a Phase 3 study should demonstrate that patients are able to maintain the baseline level of “stability” during treatment with Mycapssa®

Q4 2021	Q1 2022	Q2 2022	Q4 2022	2024
KOL Advisory Board - consideration of key elements of FDA feedback	PK data enables Amryt to proceed with planned Phase 3 study design	Written responses to a Type-C meeting request are anticipated to be received	Phase 3 initiation anticipated	Top-line data anticipated

FILSUVEZ® - POTENTIAL FIRST IN MARKET THERAPY FOR EB POST CHMP OPINION

CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB

Positive opinion based on largest ever pivotal global Phase 3 EASE study undertaken in EB

Proposed Label: for treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older

Filsuvez® would be the first and only approved treatment in Europe for EB Patients

Feb 2022	Apr 2022	Q2 2022	Jun 2022	H2 2022	2023-24
CRL received from FDA	Positive CHMP opinion	End of Review conference with FDA anticipated	Final EU approval anticipated	Initial launch in EU anticipated	Additional EU country launches anticipated

AMRYT PHARMA

SMALL NUMBER OF CENTERS TREATING MAJORITY OF EB PATIENTS IN EUROPE

United Kingdom

St Thomas'
Great Ormond Street
Birmingham

France

Necker
St. Louis
Toulouse
Nice
Bordeaux

Spain

Hospital La Paz
Hospital Sant Joan de Déu



Germany & Austria

Freiburg
Hannover
Berlin
Kiel
Cologne
Erlangen
Munich
Salzburg

Italy

Rome
Milan
Bari
Padova
Bologna

AMRYT PHARMA

EXPECTED 2022 NEWSFLOW

- European Commission (EC) approval decision on Filsuvez® anticipated by end of June
- Filsuvez® End of Review conference with FDA anticipated Q2 2022
- Mycapssa® NET program - written responses to a Type C meeting request anticipated Q2 2022
- Filsuvez® EU launch anticipated H2 2022
- Lomitapide pediatric HoFH top-line data anticipated H2 2022
- Mycapssa® EMA MAA CHMP opinion for acromegaly indication anticipated H2 2022
- Mycapssa® NET program - Phase 3 study initiation anticipated Q4 2022

Q1 2022 COMMERCIAL PRODUCT PERFORMANCE

	Q1 2022 (unaudited)			
	US	EMEA	Other	**Total**
	US$'000	US$'000	US$'000	**US$'000**
Metreleptin	20,244	15,922	1,481	**37,647**
Lomitapide	8,054	7,190	2,572	**17,816**
Mycapssa®	3,427	-	-	**3,427**
Other	-	171	68	**239**
Total revenue	**31,725**	**23,283**	**4,121**	**59,129**

	Q1 2021 (unaudited)			
	US	EMEA	Other	**Total**
	US$'000	US$'000	US$'000	**US$'000**
Metreleptin	16,239	12,971	750	**29,960**
Lomitapide	8,324	7,440	2,420	**18,184**
Mycapssa®	-	-	-	**-**
Other	-	223	65	**288**
Total revenue	**24,563**	**20,634**	**3,235**	**48,432**

IFRS AND NON-GAAP ADJUSTED RESULTS - Q1 2022 EBITDA

US$M	Q1 2022 (unaudited)	Q1 2022 Non-cash Items[1]	Q1 2022 Non-GAAP Adjusted
Revenue	**59.1**	**-**	**59.1**
Gross profit	**28.4**	**16.0**	**44.4**
R&D expenses	(9.9)	-	(9.9)
SG&A expenses	(27.7)	0.4	(27.3)
Restructuring and acquisition costs	(0.4)	-	(0.4)
Share based compensation expenses	(3.2)	3.2	-
Operating (loss) / profit before finance expense	**(12.8)**	**19.6**	**6.8[2]**
Operating (loss) / profit before finance expense and restructuring and acquisition costs	**(12.4)**	**19.6**	**7.2[2]**

1. Non-cash items include amortisation of the acquired metreleptin, lomitapide and Mycapssa® intangible assets ($14.4M), amortisation of the inventory fair value step-up related to the acquisition of Chiasma, Inc. ($1.6M), depreciation and amortisation ($0.4M) and share based compensation expenses ($3.2M).
2. EBITDA is earnings before interest, tax, depreciation, amortisation and share based compensation expenses. To supplement Amryt's financial results presented in accordance with IFRS generally accepted accounting principles, the Company uses EBITDA as a key measure of company performance as the Company believes that this measure is most reflective of the operational profitability or loss of the Company and provides management and investors with useful supplementary information which can enhance their ability to evaluate the operating performance of the business. EBITDA, as measured by the Company, is not meant to be considered in isolation or as a substitute to operating profit / loss attributable to Amryt and should be read in conjunction with the Company's condensed consolidated financial statements prepared in accordance with IFRS.

OPERATING EXPENSES





** SG&A costs are before restructuring expenses, depreciation & amortization*

AMRYT PHARMA

IFRS AND NON-GAAP ADJUSTED RESULTS - Q1 2022 EBITDA

US$M	Q1 2022 (unaudited)	Q1 2022 Non-cash Items[1]	Q1 2022 Non-GAAP Adjusted
Revenue	**59.1**	**-**	**59.1**
Gross profit	**28.4**	**16.0**	**44.4**
R&D expenses	(9.9)	-	(9.9)
SG&A expenses	(27.7)	0.4	(27.3)
Restructuring and acquisition costs	(0.4)	-	(0.4)
Share based compensation expenses	(3.2)	3.2	-
Operating (loss) / profit before finance expense	**(12.8)**	**19.6**	**6.8[2]**
Operating (loss) / profit before finance expense and restructuring and acquisition costs	**(12.4)**	**19.6**	**7.2[2]**

1. Non-cash items include amortisation of the acquired metreleptin, lomitapide and Mycapssa® intangible assets ($14.4M), amortisation of the inventory fair value step-up related to the acquisition of Chiasma, Inc. ($1.6M), depreciation and amortisation ($0.4M) and share based compensation expenses ($3.2M).
2. EBITDA is earnings before interest, tax, depreciation, amortisation and share based compensation expenses. To supplement Amryt's financial results presented in accordance with IFRS generally accepted accounting principles, the Company uses EBITDA as a key measure of company performance as the Company believes that this measure is most reflective of the operational profitability or loss of the Company and provides management and investors with useful supplementary information which can enhance their ability to evaluate the operating performance of the business. EBITDA, as measured by the Company, is not meant to be considered in isolation or as a substitute to operating profit / loss attributable to Amryt and should be read in conjunction with the Company's condensed consolidated financial statements prepared in accordance with IFRS.

CASH



AMRYT PHARMA

Q1 2022 DEBT REFINANCING

$125 Million
Non-Dilutive Debt Refinancing (February 2022)

$85 Million — Term Loan Facility (fully drawn)

$40 Million — Revolving Credit Facility ($20 million drawn at close)

1. Reduction in interest rate 13% (old facility) → 6.8% (blended)
2. Change in principal repayment from September 2024 to February 2027
3. No warrants or any equity conversion features associated with the new facilities
4. Facility provided by Credit Group of Ares Management Corporation

New Facilities Will Significantly Reduce Amryt's Interest Expense and Cost of Capital and Extend Term Debt Maturity Through 2027

AMRYT - A GLOBAL LEADER IN RARE DISEASES

Revenue generating commercial portfolio with three approved products, driving EBITDA, and strong positive operating cashflows

Significant development pipeline with multiple near and medium-term growth drivers

AMRYT PHARMA

Track record of successful acquisition, integration, performance and growth

Global commercial infrastructure, financial flexibility and experienced team in place to drive product growth

*Management estimates

Questions & Answers

AMRYT PHARMA